Duchesne GM - Search Results

1

A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.

Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph DJ, Lim TS, Matthews J, Millar J, Sidhom M, Spry NA, Tang CI, Turner S, Williams SG, Wiltshire K, Woo HH, Kneebone A. Pearse M, et al. Among authors: duchesne gm. BJU Int. 2014 Mar;113 Suppl 2:7-12. doi: 10.1111/bju.12623. BJU Int. 2014. PMID: 24894850 Clinical Trial.

2

Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies.

Duchesne GM, Bloomfield D, Wall P. Duchesne GM, et al. Radiother Oncol. 1996 Jan;38(1):7-12. doi: 10.1016/0167-8140(95)01645-7. Radiother Oncol. 1996. PMID: 8850420

3

Management of localised prostate cancer: state of the art.

Frydenberg M, Duchesne G, Stricker PD. Frydenberg M, et al. Med J Aust. 1998 Jul 6;169(1):11-2. doi: 10.5694/j.1326-5377.1998.tb141468.x. Med J Aust. 1998. PMID: 9695693 Review. No abstract available.

4

Measurement of lung tumor volumes using three-dimensional computer planning software.

Bowden P, Fisher R, Mac Manus M, Wirth A, Duchesne G, Millward M, McKenzie A, Andrews J, Ball D. Bowden P, et al. Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):566-73. doi: 10.1016/s0360-3016(02)02783-9. Int J Radiat Oncol Biol Phys. 2002. PMID: 12062598

5

Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study.

Duchesne GM, Dowling C, Frydenberg M, Joseph D, Gogna NK, Neerhut G, Roberts S, Spry N, Turner S, Woo H. Duchesne GM, et al. Urology. 2003 Jan;61(1):179-83. doi: 10.1016/s0090-4295(02)02005-8. Urology. 2003. PMID: 12559292

6

What to do for prostate cancer patients with a rising PSA?--A survey of Australian practice.

Duchesne GM, Millar JL, Moraga V, Rosenthal M, Royce P, Snow R. Duchesne GM, et al. Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):986-91. doi: 10.1016/s0360-3016(02)04213-x. Int J Radiat Oncol Biol Phys. 2003. PMID: 12605977

7

Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.

Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Kovacev O, Robertson R, Francis L, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G. Lamb DS, et al. Radiother Oncol. 2003 Sep;68(3):255-67. doi: 10.1016/s0167-8140(03)00193-2. Radiother Oncol. 2003. PMID: 13129633 Clinical Trial.

8

What defines intermediate-risk prostate cancer? Variability in published prognostic models.

Williams SG, Millar JL, Dally MJ, Sia S, Miles W, Duchesne GM. Williams SG, et al. Among authors: duchesne gm. Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):11-8. doi: 10.1016/s0360-3016(03)00820-4. Int J Radiat Oncol Biol Phys. 2004. PMID: 14697415

9

Assessment of i-125 prostate implants by tumor bioeffect.

Haworth A, Ebert M, Waterhouse D, Joseph D, Duchesne G. Haworth A, et al. Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1405-13. doi: 10.1016/j.ijrobp.2004.01.047. Int J Radiat Oncol Biol Phys. 2004. PMID: 15275726

10

Prostate implant evaluation using tumour control probability--the effect of input parameters.

Haworth A, Ebert M, Waterhouse D, Joseph D, Duchesne G. Haworth A, et al. Phys Med Biol. 2004 Aug 21;49(16):3649-64. doi: 10.1088/0031-9155/49/16/012. Phys Med Biol. 2004. PMID: 15446795

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters